N/A N=640 Understanding Alcohol Reward in Social Context
Alcohol Drinking · Alcohol Use Disorder · Alcohol Intoxication
Primary: Self-Reported Emotion — 3.49; 2.98; 0.32; 0.673 score on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=54 A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
Mental Disorder · Schizophrenia · Major Depressive Disorder
Primary: Cohort 1: Positive Detection Accuracy (PDA) of D-Tect Patch — 100 percentage of detections
N/A N=119 Pulsed Electromagnetic Fields for Postoperative Analgesia: A Randomized, Triple-Masked, Sham-Controlled Pilot Study
Postoperative Pain, Acute
Primary: AVERAGE Pain Measured With the Numeric Rating Scale — 2.4; 2.6 score on a scale
Phase 2 N=6 MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Number of Participants With Dose Limiting Toxicities (DLT) [Phase I] — 1 Participants
N/A N=35 Characterization of Selected Aerosol Constituents Levels in the Exhaled Breath of Adult e-Vapor Users
Tobacco Use
Primary: Nicotine Residue Summary Statistics by Test-Product Group — 87.1; 192.3; 174.1; 182.8 Micrograms
Phase 2 N=447 Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
Chronic Kidney Disease
Primary: Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12 — 0.48; 0.72 milligram/gram (mg/g) — p=<0.001
N/A N=479 Unmet Social Needs Study
Cardiovascular Disease · Hypertension · Diabetes Mellitus
Primary: Number of Participants Who Connected With a New Resource — 40; 41; 51 Participants — p=0.6243
Phase 4 N=25 A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Participants With American College of Rheumatology (ACR) 20 Response at Week 14 — 9 participants
N/A N=70 Positive Psychology Intervention In HSCT
Hematologic Malignancy · Hematopoietic/Lymphoid Cancer · Blood Cancer
Primary: Feasibility Rate — 31 Participants
Phase 2 N=55 Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females
HIV Infections
Primary: Count and Percentage of Participants Experiencing Any Grade 2 or Higher Clinical Adverse Events (AEs) and Laboratory Abnormalities Among Participants Who Receive at…
N/A N=40 Assessment of Body Composition and Physical Function
Body Composition · Physical Function
Primary: Fat Mass — 44.71 Kg
N/A N=378 Study of BD Pre-filled Flush Syringes in China
Effectiveness and Safety of Pre-filled Flush Syringe
Primary: the Overall Performance for Flushing and / or Locking the Catheters. — 187; 185 participants
Phase 2 N=85 A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
Multiple Myeloma
Primary: Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2 — 12 Participants
N/A N=96 Comparing Two Anesthetic Techniques for Implant Placement
Edentulous Jaw · Dental Implant · Anesthesia, Local
Primary: Pain Perception by Numerical Rating Scale — 0; 0 score on a scale
Phase 3 N=1,455 AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
COVID-19
Primary: Number of Participants With Sustained Recovery — 617; 594 Participants